TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28279086
Drug: Financial incentives
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Financial incentives for medication compliance (0, 1, 2, or 3 incentives awarded quarterly over 1 year)
Study: 25191766
Drug: alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-lipoic acid (LA) supplementation (500 mg/day) for three months
Study: 22027944
Drug: Red ginseng
Normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red ginseng (3 g per day, including 60 mg of ginsenosides)
Study: 20501928
Drug: Reports with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reports with spin focusing only on treatment effectiveness
Study: 18520980
Drug: 200-mg retarded-release
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-mg retarded-release levodopa/carbidopa (LD/CD)
Study: 18520980
Drug: 150-mg levodopa/carbidopa/entacapone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150-mg levodopa/carbidopa/entacapone (LD/CD/EN)
Study: 1828336
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (2.04 g/d)
Study: 1828336
Drug: safflower oil
Normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: safflower oil (4.8 g/d of linoleic acid)
Study: 116282
Drug: Oxprenolol (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (480 mg)
Study: 30612727
Drug: Insulin-treated diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-treated diabetes mellitus (ITDM)
Study: 30612727
Drug: Non-insulin treated
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-insulin treated diabetes mellitus (NITDM)
Study: 17974868
Drug: Multicomponent behavioral
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent behavioral treatment (MBT)
Study: 11666123
Drug: TTFCA (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFCA (total triterpenic fraction of Centella asiatica), 60 mg twice daily for 6 weeks
Study: 8053015
Drug: Intramuscular sulfadoxine‐pyrimethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular sulfadoxine‐pyrimethamine
Study: 29550012
Drug: No glide
Normalized name: Chamois Glide
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No glide path preparation
Study: 24646034
Drug: Aerosolized antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized antibiotics (AA) given for 14 days or until extubation.
Study: 16027801
Drug: Probucol 250
Normalized name: probucol 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 250 mg/day for 7-10 days before and 6 months after angioplasty
Study: 16027801
Drug: Probucol 250
Normalized name: probucol 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 250 mg/day for 6 months after angioplasty
Study: 16027801
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no probucol therapy)
Study: 6346782
Drug: Cimethidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimethidine 400 mg intramuscularly as pre-anesthetic
Study: 29121432
Drug: Alpine climate
Normalized name: Alpine strawberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpine climate treatment (6-week personalized integrative multidisciplinary treatment in Switzerland)
Study: 29121432
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment in moderate maritime climate (Netherlands)
Study: 21636667
Drug: Fluticasone/Salmeterol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/Salmeterol combination (FP/SM) 125/25 μg, two puffs bid for 2 weeks
Study: 21636667
Drug: Fluticasone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (250 μg), two puffs bid for 2 weeks
Study: 21636667
Drug: Fluticasone/Salmeterol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/Salmeterol combination (FP/SM)
Study: 21636667
Drug: Fluticasone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (250 μg)
Study: 20237772
Drug: 900 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg/day OXC
Study: 20237772
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day CBZ
Study: 15196300
Drug: Valproate 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate 1000 mg
Study: 11521982
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to H. pylori in Group A (S-PGI <25 microg/l) and Group C (S-PGI >100 microg/l)
Study: 11521982
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to CagA in relation to S-PGI levels
Study: 11521982
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to CagA in relation to severity of atrophic gastritis
Study: 9475824
Drug: Zinc lozenges
Normalized name: Zinc Lozenges
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc lozenges (zinc gluconate)
Study: 2501852
Drug: Au parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Au parenteral preparations
Study: 2501852
Drug: D-penicillamine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine (average daily dose of 450 mg)
Study: 78625
Drug: Trioxsalen baths
Normalized name: Trioxsalen
DrugBank: Trioxsalen (DB04571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trioxsalen baths (0.5 mg/1) for 15 minutes followed by irradiation with dysprosium lamps (Osram HQI‐TS)
Study: 78625
Drug: Methoxsalen bath
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methoxsalen bath (1 mg/l)
Study: 25339740
Drug: DLPFC activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DLPFC activation during antisaccade preparation in ALS patients
Study: 23097397
Drug: Pigs on
Normalized name: guinea pig dander
DrugBank: Cavia porcellus dander (DB11019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pigs on the Bt/Bt treatment
Study: 20394489
Drug: Mometasone cream
Normalized name: mometasone Topical Cream
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone cream (0.1%) once daily
Study: 20394489
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream (1%) twice daily
Study: 15101860
Drug: Pre group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre group (promethazine 0.1 mg kg(‐1) before anaesthesia)
Study: 15101860
Drug: Post group
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post group (saline before anaesthesia, promethazine 0.1 mg kg(‐1) postoperatively)
Study: 11273253
Drug: Polyunsaturated phosphatidyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyunsaturated phosphatidyl choline (PPC) 350 mg thrice daily for 6 to 8 weeks
Study: 18515458
Drug: Lithium-valproate combination
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium-valproate combination
Study: 11688904
Drug: Interferon-alpha monotherapy
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha monotherapy
Study: 3300975
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg isosorbide 5‐mononitrate
Study: 3300975
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg isosorbide 5‐mononitrate
Study: 3300975
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg isosorbide 5‐mononitrate
Study: 31488733
Drug: Noradrenergic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenergic and serotonergic antidepressants with 100 mg acetylsalicylic acid (ASA)
Study: 31488733
Drug: Noradrenergic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenergic and serotonergic antidepressants without 100 mg acetylsalicylic acid (ASA)
Study: 31488733
Drug: Noradrenergic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenergic and serotonergic antidepressants (both with and without ASA)
Study: 20338501
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow mononuclear cell therapy (BMC therapy)
Study: 20338501
Drug: Higher numbers
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher numbers of RBCs in BMC preparation
Study: 17403067
Drug: First offender
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First offender incarceration and treatment program
Study: 17403067
Drug: First offender
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First offender incarceration and treatment program (for ASPD participants)
Study: 17403067
Drug: First offender
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First offender incarceration and treatment program (relative to control)
Study: 15831714
Drug: Naloxone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (80 microg/kg iv bolus injection)
Study: 3043355
Drug: doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxycycline (200 mg once daily)
Study: 29445655
Drug: Nonextensible lumbosacral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonextensible lumbosacral orthosis (LSO) in addition to routine physical therapy
Study: 25458446
Drug: Ultrasound and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound and electrical stimulator guided obturator nerve block using 5% phenol in aqueous solution
Study: 20817628
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to salt based wood protection agents
Study: 19273451
Drug: Abatacept 2
Normalized name: abatacept 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept 2 mg/kg
Study: 12945222
Drug: Bisoprolol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 2.5 mg/HCTZ 6.25 mg
Study: 12945222
Drug: Bisoprolol 5
Normalized name: bisoprolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 5 mg/HCTZ 6.25 mg
Study: 12945222
Drug: Continuation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation with Bisoprolol 2.5 mg/HCTZ 6.25 mg for 4 more weeks
Study: 12945222
Drug: Up-titration to
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up-titration to Bisoprolol 5 mg/HCTZ 6.25 mg
Study: 8373709
Drug: Yohimbine (alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (alpha 2‐adrenoceptor antagonist)
Study: 8373709
Drug: Standing after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standing after yohimbine administration
Study: 25775165
Drug: Metformin arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin arm
Study: 26588822
Drug: Instruction with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instruction with sham treatment (peppermint essence vapor)
Study: 26588822
Drug: Conditioning with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioning with sham treatment (peppermint essence vapor)
Study: 26588822
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of instruction and conditioning
Study: 21193234
Drug: Effective radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective radiation dose for MDCT‐XTe
Study: 21193234
Drug: Effective radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective radiation dose for MDCT‐XT
Study: 21193234
Drug: Effective radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective radiation dose for MDCT‐Helical
Study: 15943841
Drug: famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 20 mg b.d. (n = 48)
Study: 15943841
Drug: omeprazole once
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: omeprazole once daily (n = 50)
Study: 6280836
Drug: BCG immunotherapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG immunotherapy (1 vial of high viability Pasteur BCG by scarification technique on days 8 and 15 of each 21-28 day treatment cycle)
Study: 6280836
Drug: BCG immunotherapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG immunotherapy (for patients who responded and survived longer than one year)
Study: 6280836
Drug: No BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No BCG immunotherapy (for patients who responded and survived longer than one year)
Study: 25421470
Drug: Micafungin 2
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micafungin 2 mg/kg/day
Study: 25421470
Drug: Micafungin 1
Normalized name: micafungin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin 1 mg/kg/day
Study: 25421470
Drug: Micafungin 3
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micafungin 3 mg/kg/day
Study: 21851025
Drug: Infusion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion therapy controlled by transesophageal dopplerography (Cardio Q apparatus)
Study: 21851025
Drug: Infusion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion therapy assessed clinically (BP, CVP, HR, diuresis)
Study: 21851025
Drug: Infusion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion therapy controlled by transesophageal dopplerography
Study: 21851025
Drug: Infusion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion therapy assessed clinically
Study: 17392668
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine analgesia (control)
Study: 17392668
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intravenous morphine)
Study: 9932219
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Lispro (5 min before the meal)
Study: 9932219
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (20 min before the meal)
Study: 8092452
Drug: midazolam, 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam, 0.2 mg/kg BW orally
Study: 8092452
Drug: nordazepam, 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: nordazepam, 0.2 mg/kg BW orally
Study: 8092452
Drug: atropine, 0.5
Normalized name: Isopto Atropine, 0.5% ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: atropine, 0.5 mg, plus promethazine, 50 mg i.m.
Study: 8092452
Drug: atropine, 0.5
Normalized name: Isopto Atropine, 0.5% ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: atropine, 0.5 mg, plus promethazine, 50 mg, plus pethidine, 0.7 mg/kg BW i.m.
Study: 12820857
Drug: Cortisol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (10 mg)
Study: 11208406
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 40 mg
Study: 11208406
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 80 mg
Study: 7058754
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 120 mg
Study: 11208406
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 40 mg in 3x phase
Study: 11208406
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 80 mg in 2x phase
Study: 11208406
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 80 mg in once-daily phase
Study: 11208406
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 120 mg in once-daily phase
Study: 8879340
Drug: Beta‐adrenoceptor blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta‐adrenoceptor blocker (atenolol)
Study: 1642341
Drug: Serum thiopental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum thiopental concentration of 10-30 micrograms/ml for 5 min
Study: 1642341
Drug: Higher serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher serum thiopental concentration of 40-90 micrograms/ml
Study: 6380114
Drug: Herbazol A
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbazol A (with antacid component)
Study: 6380114
Drug: Herbacid B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbacid B (without antacid component)
Study: 29351646
Drug: Postpartum training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postpartum training program (weekly supervised exercise class focusing on pelvic floor muscle strength training and daily home training)
Study: 29693865
Drug: Sildenafil monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil monotherapy
Study: 23348043
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (EX) - core strengthening home exercise program thrice weekly for 6 weeks
Study: 23706759
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg once or twice daily)
Study: 20502283
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg orally twice daily for 5 days at the onset of bleeding)
Study: 18556141
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) with absorbed dose >1.0 Gy to the contralateral breast (CB)
Study: 18556141
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) with absorbed dose to the contralateral breast (CB)
Study: 16670154
Drug: 8% CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% CHO solution
Study: 12792873
Drug: Killed whole-promastigote
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole-promastigote vaccine cocktail plus BCG adjuvant
Study: 8457502
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg of oral acetazolamide (group A)
Study: 21058884
Drug: Auricular acupressure
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupressure (stimulator tapping and regular massage twice a day for 4 weeks)
Study: 16606763
Drug: Trientine hydrochloride
Normalized name: Trientine Hydrochloride
DrugBank: Triethylenetetramine (DB06824)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Trientine hydrochloride 500 mg 2 times per day plus 50 mg of zinc 2 times per day
Study: 16606763
Drug: Tetrathiomolybdate 20
Normalized name: Tetrathiomolybdate
DrugBank: Tetrathiomolybdate (DB05088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrathiomolybdate 20 mg 3 times per day with meals and 20 mg 3 times per day between meals plus 50 mg of zinc 2 times per day
Study: 10946883
Drug: Cyclical etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclical etidronate (200 mg/day for 2 weeks every 3 months)
Study: 1428733
Drug: Vindesine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine (2 mg/M2/dose) plus Prednisone (60 mg/M2/dose)
Study: 1428733
Drug: Vincristine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine (2 mg/M2/dose) plus Prednisone (60 mg/M2/day)
Study: 3897404
Drug: Levamisole 150
Normalized name: levamisole 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole 150 mg/day for three consecutive days for three months
Study: 27430123
Drug: APL-130277 10
Normalized name: APL-502
DrugBank: APL-502 (DB17473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APL-130277 10 mg
Study: 27430123
Drug: APL-130277 (dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: APL-130277 (dosing up to 30 mg if needed)
Study: 25255346
Drug: Intranasal septal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal septal splints
Study: 18620950
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine and amodiaquine
Study: 11556655
Drug: heparin 5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin 5,000 units s.c.
Study: 9597562
Drug: Nicardipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (40 mg)
Study: 8165070
Drug: Prenatal dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prenatal dexamethasone (DEX) treatment (6 mg four times at 12-hour intervals)
Study: 8165070
Drug: Prenatal dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prenatal dexamethasone (DEX) treatment combined with exogenous human surfactant therapy
Study: 24867846
Drug: Frovatriptan 2.5
Normalized name: frovatriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan 2.5 mg (Frova)
Study: 19244152
Drug: Psyllium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium supplementation (14 g/day for 3 months)